Upadacitinib治疗肛周克罗恩病一年真实世界疗效:GETAID研究
这项法国多中心回顾性队列纳入59例活动性肛周克罗恩病患者,均曾暴露于至少一种生物制剂。UPA治疗12个月时,瘘管型患者临床缓解率为26%,孤立性肛周溃疡愈合率为25%,MRI缓解率仅8%。
要点
- UPA在难治性肛周CD中1年临床缓解率约四分之一
- 瘘管型pCD患者12个月临床缓解11/43(26%),应答13/43(30%)
- 孤立性肛周溃疡12个月完全愈合4/16(25%)
核心结论
- 在难治性肛周克罗恩病真实世界队列中,UPA治疗1年时约四分之一患者达到临床缓解。
研究设计与样本
- 法国13个中心开展的回溯性队列研究,纳入2022年9月至2025年8月连续接受UPA治疗的活动性pCD患者59例。
- 临床结局采用非应答者插补分析,MRI结局按实际观察分析。
主要发现
- 59例患者中43例(73%)为瘘管型pCD,16例(27%)为孤立性肛周溃疡;所有患者既往至少暴露于一种生物制剂,瘘管型中79%曾接受肛周手术。
- 瘘管型pCD患者6个月和12个月临床缓解均为11/43(26%),临床应答分别为21/43(49%)和13/43(30%)。
- 12个月时瘘管型pCD患者MRI应答9/13(69%),MRI缓解1/13(8%)。
- 孤立性肛周溃疡患者3、6、12个月完全愈合分别为5/16(31%)、4/16(25%)、4/16(25%)。
- 瘘管型pCD患者中未发现预测临床缓解的因素。
关键数值与推荐
- 临床缓解定义为无瘘管引流(自发性或轻压时)且肛周溃疡愈合,未启动新治疗。
- 临床应答定义为基于医师评估的瘘管和/或溃疡改善≥50%。
临床怎么用
- 对于既往生物制剂暴露的难治性肛周CD,UPA可作为治疗选择之一,但1年临床缓解率有限,需管理预期。
- MRI缓解率较低,提示临床缓解者仍需关注影像学活动性。
局限性
- 回顾性设计,样本量较小(59例),部分结局采用非应答者插补分析。
- MRI结局仅基于实际观察的少数患者(13例),数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD (pCD) remain limited. METHODS: All consecutive patients with active pCD (primary and/or secondary lesions) treated with UPA across 13 French centres between September 2022 and August 2025 were included in a retrospective cohort study. Clinical remission was defined as absence of fistula drainage (spontaneous or on gentle pressure) and healing of anal ulcerations without initiation of new therapy. Clinical response was defined as ≥ 50% improvement in fistulas and/or ulcerations based on physician assessment. Clinical outcomes were analysed using non-responder imputation, and magnetic resonance imaging (MRI) outcomes as observed. RESULTS: Among the 59 patients included, 43 (73%) had fistulizing pCD and 16 (27%) isolated anal ulcerations. All patients were previously exposed to at least one biologic and 79% of those with fistulizing pCD underwent prior perianal surgery. In patients with fistulizing pCD, clinical remission was achieved in 11/43 (26%) and 11/43 (26%) patients at 6 and 12 months, respectively, clinical response in 21/43 (49%) and 13/43 (30%) patients. At 12 months, MRI response was documented in 9/13 (69%) and MRI remission in 1/13 (8%) patients with fistulizing pCD. Among patients with fistulizing pCD, no factors predicted clinical remission. Among patients with isolated anal ulcerations, complete healing occurred in 5/16 (31%) at 3 months, 4/16 (25%) at 6 months and 4/16 (25%) at 12 months. CONCLUSION: In this real-world cohort of refractory pCD, UPA achieved clinical remission in one-quarter of patients at 1 year.
引用
- Richard N, Seksik P, Altwegg R, et al. One-Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real-World GETAID Study. Aliment Pharmacol Ther. 2026. PMID: 42045621. doi:10.1111/apt.70682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。